LEVEL 38, MELBOURNE, VICTORIA, C3
Market cap: $2.2B (2/19/2026)
Price: $16.88
Financial Results and Corporate Update Webcast
High Survival Rates with Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults with SR-aGvHD
Net Revenues Increase for the Quarter to US$30M
Real-World Commercial Experience Shows 84% Survival Of Children With SR-aGvHD After Completing 28-Days Of Treatment
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Appendix 3G - Notification of Issue, Conversion or Payment Up of Unquoted Equity Securities
Change of Director’s Interest Notice
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Amended Schedule 13G - Ownership Report
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Correspondence
Submission Upload